Oncology Institute Inc [TOI] stock prices are up 5.21% to $3.23 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TOI shares have gain 3.53% over the last week, with a monthly amount drifted -23.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oncology Institute Inc [NASDAQ: TOI] stock has seen the most recent analyst activity on November 25, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $5. Previously, Noble Capital Markets started tracking the stock with Outperform rating on July 23, 2025, and set its price target to $8. On July 16, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $6 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $7 on May 15, 2025. Guggenheim started tracking with a Buy rating for this stock on September 14, 2022, and assigned it a price target of $7. In a note dated August 15, 2022, Jefferies initiated a Buy rating and provided a target price of $10 on this stock.
The stock price of Oncology Institute Inc [TOI] has been fluctuating between $0.17 and $4.88 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Oncology Institute Inc [NASDAQ: TOI] shares were valued at $3.23 at the most recent close of the market. An investor can expect a potential return of 54.8% based on the average TOI price forecast.
Analyzing the TOI fundamentals
The Oncology Institute Inc [NASDAQ:TOI] reported sales of 461.04M for trailing twelve months, representing a surge of 36.70%. Gross Profit Margin for this corporation currently stands at 0.15% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is 21.04 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.09 points at the first support level, and at 2.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.34, and for the 2nd resistance point, it is at 3.46.
Ratios To Look Out For
It’s worth pointing out that Oncology Institute Inc [NASDAQ:TOI]’s Current Ratio is 1.68. Further, the Quick Ratio stands at 1.39, while the Cash Ratio is 0.42. Considering the valuation of this stock, the price to sales ratio is 0.69.
Transactions by insiders
Recent insider trading involved Pacala Mark L, Director, that happened on Nov 18 ’25 when 50000.0 shares were sold. Director, MARK PACALA completed a deal on Nov 18 ’25 to buy 50000.0 shares. Meanwhile, Director M33 Growth I L.P. sold 6.02 million shares on Sep 04 ’25.
